Mary E. Rinella, MD is a Professor of Medicine in the Gastroenterology, Hepatology and Nutrition section at the University of Chicago since January 2021. She is the director of the Metabolic and Fatty Liver Program as well as Director of Clinical trials for the section.
She has held several national societal leadership roles, including on the Governing Board of the American Association for the Study of Liver Disease (AASLD). She was lead author of the 2023 AASLD Clinical Practice Guidance on the diagnosis and management of NAFLD, now MASLD. She recently led a multi-society global effort to revise the nomenclature of NAFLD and served as Chair of the AASLD Steatotic Liver Disease (SLD) task force, charged with increasing disease awareness, disseminating best practice, developing a national strategy and fortifying global collaborations to improve care and outcomes of patients with SLD.
The metabolic (fatty liver) liver clinic provides multidisciplinary care to patients in collaboration with an obesity medicine specialist as well as a dietician to provide individualized, patient-centered care. Here patients have access to the latest approved therapies as well as clinical trials with emerging therapies. While her research and clinical focus is metabolic liver disease, she has significant expertise and interest in cholestatic liver disease, including PBC and PSC and autoimmune liver disease, as well as in complications of cirrhosis and portal hypertension.
Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis.
Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2025 Nov; 10(11):998-1012.
PMID: 40953570
Phosphatidylethanol in steatotic liver disease.
Phosphatidylethanol in steatotic liver disease. J Hepatol. 2025 Nov; 83(5):1189-1203.
PMID: 40759197
The People-First Liver Charter.
The People-First Liver Charter. Nat Med. 2025 Jul; 31(7):2109-2116.
PMID: 40473951
Call to action-Pediatric MASLD requires immediate attention to curb health crisis.
Call to action-Pediatric MASLD requires immediate attention to curb health crisis. Hepatology. 2025 Nov 01; 82(5):1341-1351.
PMID: 40550108
Determining Cirrhosis Status in Candidates for Resmetirom.
Determining Cirrhosis Status in Candidates for Resmetirom. Clin Gastroenterol Hepatol. 2025 Nov; 23(12):2061-2063.
PMID: 40354924
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH.
Efruxifermin in Compensated Liver Cirrhosis Caused by MASH. N Engl J Med. 2025 Jun 26; 392(24):2413-2424.
PMID: 40341827
Fecal Butyrate and Deoxycholic Acid Concentrations Correlate With Mortality in Patients With Liver Disease.
Fecal Butyrate and Deoxycholic Acid Concentrations Correlate With Mortality in Patients With Liver Disease. Gastro Hep Adv. 2025; 4(8):100695.
PMID: 40574876
Awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) in 4 major cities in the United States.
Awareness of metabolic dysfunction-associated steatotic liver disease (MASLD) in 4 major cities in the United States. Hepatol Commun. 2025 May 01; 9(5).
PMID: 40331869
Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.
Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025 Jun 05; 392(21):2089-2099.
PMID: 40305708
An Expert Consensus Delphi Panel in Metabolic Dysfunction- and Alcohol-associated Liver Disease: Opportunities and Challenges in Clinical Practice.
An Expert Consensus Delphi Panel in Metabolic Dysfunction- and Alcohol-associated Liver Disease: Opportunities and Challenges in Clinical Practice. Clin Gastroenterol Hepatol. 2026 Mar; 24(3):633-645.e4.
PMID: 40315973